Panelists discuss how logistical barriers like drug access, insurance coverage, and managing infusion logistics have posed challenges in the implementation of GPRC5D-targeted therapies in community practice.
What logistical barriers have you encountered in implementing GPRC5D-targeted therapies in your community practice (e.g., access, coverage, infusion logistics)?